Reported 2 months ago
Gilead Sciences reported a significant profit of $2.01 per share for Q2, surpassing Wall Street estimates mainly due to decreased operating costs and increased product sales, resulting in a revenue of $7 billion. The company raised its full-year profit outlook, despite facing challenges in its solid tumor oncology segment, while HIV drug sales remained strong. The share price rose slightly following the announcement, reflecting a positive response to the quarter's performance and anticipated drug approvals.
Source: YAHOO